Abstract:In response to the urgent need for potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics, this study introduces an innovative nucleoside tailoring strategy leveraging ribonuclease targeting chimeras. By seamlessly integrating ribonuclease L recruiters into nucleosides, we address RNA recognition challenges and effectively inhibit severe acute respiratory syndrome coronavirus 2 replication in human cells. Notably, nucleosides tailored at the ribose 2′-position outperform those modified at the nucleobase. Our in vivo validation using hamster models further bolsters the promise of this nucleoside tailoring approach, positioning it as a valuable asset in the development of innovative antiviral drugs.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop effective treatments against SARS - CoV - 2 (the virus that causes COVID - 19). Specifically, the researchers introduced an innovative nucleoside modification strategy to enhance the antiviral effect of nucleosides by using ribonuclease - targeting chimera (RIBOTAC). This method aims to overcome RNA recognition challenges and effectively inhibit the replication of SARS - CoV - 2 in human cells by introducing a ribonuclease L recruitment module at specific positions of nucleosides (such as the 2′ - site of ribose). The study also verified the effectiveness of this nucleoside modification strategy through in vivo experiments, showing its great potential in antiviral drug development. ### Core issues: 1. **Developing effective anti - SARS - CoV - 2 treatments**: - Research background: The high mutation rate of the SARS - CoV - 2 virus makes traditional antiviral drug development challenging, and new strategies are needed to improve the efficacy and safety of drugs. - Solution: Through the nucleoside modification strategy, especially using RIBOTAC technology, design new nucleoside analogues that can effectively inhibit virus replication. 2. **Optimizing the nucleoside modification strategy**: - Research finding: Nucleoside analogues modified at the 2′ - site of ribose have better effects than those modified at the base position, showing stronger antiviral activity. - Mechanism verification: Through chemical synthesis, cell experiments, and animal experiments, the key role of the RIBOTAC module in nucleoside modification and its inhibitory effect on virus replication were verified. ### Main methods: - **Chemical synthesis**: Synthesize nucleoside analogues with different modification positions, including 2′ - RIBOTAC - U and 5 - RIBOTAC - U. - **Cell experiments**: Use the Huh7 - ACE2 cell line to evaluate the antiviral effects of these nucleoside analogues, and analyze the expression levels of viral RNA and proteins by RT - qPCR and Western blot. - **Animal experiments**: Further verify the in vivo antiviral effects of the nucleoside - RIBOTAC modification strategy in the Syrian golden hamster model, and analyze the distribution and expression of the virus in lung tissues by RT - qPCR, Western blot, and immunohistochemistry. ### Main conclusions: - **The superiority of 2′ - RIBOTAC - U**: In cell and animal experiments, 2′ - RIBOTAC - U showed significant antiviral effects, with a low EC50 value and no cytotoxicity at high concentrations. - **The importance of the RIBOTAC module**: The structurally intact RIBOTAC module is crucial for the antiviral activity of nucleoside analogues, and any structural change will significantly reduce its effect. - **In vivo verification**: In the Syrian golden hamster model, 2′ - RIBOTAC - U can effectively inhibit the replication of SARS - CoV - 2 in lung tissues, showing strong antiviral ability. Through these studies, the paper provides important theoretical basis and technical support for the development of new anti - SARS - CoV - 2 drugs.

Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera

Efficient Inhibition of SARS‐CoV‐2 Using Chimeric Antisense Oligonucleotides Through RNase L Activation**

Chain Termination Effects of Chemically Modified Nucleoside Analogs on SARS-CoV-2 RNA Polymerase

2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2

Structural basis for repurpose and design of nucleoside drugs for treating COVID-19

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2

Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses

Development of a Simple in Vitro Assay to Identify and Evaluate Nucleotide Analogs Against SARS-CoV-2 RNA-Dependent RNA Polymerase

Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase

Studying the intersection of nucleoside modifications and SARS-CoV-2 RNA-dependent RNA transcription using an in vitro reconstituted system

SARS-CoV-2 couples evasion of inflammatory response to activated nucleotide synthesis

Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA

Prophylactic and Therapeutic Effects of Small Interfering RNA Targeting SARS-coronavirus.

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective

Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics

1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication

Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine

Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals

An Effective Platform for SARS-CoV-2 Prevention by Combining Neutralization and RNAi Technology